Bipolar Depression Market Analysis, Industry Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Bipolar Depression Market

DelveInsight’s “Bipolar Depression Market Insights and Forecast Report” delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends, pipeline scenario, Bipolar Depression market drivers, barriers, and forecasted analysis in the 7MM for the study period 2019-32.

 

Some Facts of Bipolar Depression Market:

As per DelveInsight analysts, the total diagnosed prevalent population of Bipolar Depression in the 7MM was 1,857,545 in 2017.
The estimates show the highest diagnosed prevalence of Bipolar Depression in the United States with 740,715 cases in 2017.
Bipolar I and Bipolar II are the major subtypes of BD.
In 2017, out of the total diagnosed prevalent population of 740,715 cases in the US for Bipolar Depression, 291,134 and 449,581 cases were contributed by Bipolar I disorder and Bipolar II disorder, respectively.

 

Scope of the Bipolar Depression Market Report:

The Bipolar Depression report covers the descriptive overview of Bipolar Depression, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Bipolar Depression epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Bipolar Depression are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Bipolar Depression market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The Bipolar Depression report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bipolar Depression market

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market

 

Bipolar Depression (Manic depression) is categorized by recurrent-shifts in the mood/temper and is a manic-depressive disorder hindering the routine life of an individual.

The American Psychiatric Association categorizes Bipolar Depression into four major types of Bipolar Depression: Bipolar I disorder, Bipolar II disorder, Cyclothymic disorder, and Bipolar Depression due to another medical or substance abuse disorder.

 

Bipolar Depression affects about 45 million people worldwide, says WHO.

 

Bipolar Depression Market: Marketed, and Upcoming Drugs

FDA-approved agents for the acute treatment of bipolar depression include Olanzapine-fluoxetine combination, Lurasidone, and Quetiapine.

Other off-label therapies present in the Bipolar Depression market are Anticonvulsants (such as Divalproex and lamotrigine), olanzapine monotherapy, and Lithium and lamotrigine combined therapy.

The Bipolar Depression market report covers detailed picture of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. The report helps in providing a better understanding of clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market

 

Bipolar Depression Drugs Covered are:

Vraylar (Cariprazine)
Latuda (Lurasidone Hydrochloride)
Abilify (Aripiprazole)
 Lumateperone/ITI-007
NRX-100/NRX-101
Psilocybin
Zuranolone (SAGE-217)
SEP-4199
ILT101
Falkieri (Esketamine DPI)
And Many Others

 

Some of the Key Bipolar Depression Companies Covered:

Allergan (AbbVie)/Gedeon Richter
Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
Otsuka Pharmaceutical
Intra-cellular Therapies
NeuroRx
COMPASS Pathways
Sage Therapeutics
Sunovion/Sumitomo Dainippon Pharma
Iltoo Pharma
Celon Pharma
And Many Others

 

 

Bipolar Depression Report Highlights

In the coming years, the Bipolar Disorder (Manic Depression) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Disorder (Manic Depression) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
Major players are involved in developing therapies for Bipolar Disorder (Manic Depression). The launch of emerging therapies will significantly impact the Bipolar Disorder (Manic Depression) market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bipolar Disorder (Manic Depression)
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities 

 

Table of Contents

1. Key Insights

2. Executive Summary of Bipolar Depression   

3. Competitive Intelligence Analysis for Bipolar Depression   

4. Bipolar Depression: Market Overview at a Glance

5. Bipolar Depression: Disease Background and Overview

6. Patient Journey

7. Bipolar Depression Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Bipolar Depression Treatment

11. Marketed Products

12. Emerging Therapies

13. Bipolar Depression: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Bipolar Depression   

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market